Compare BridgeBio Pharma Inc (BBIO) vs Wendys Co (WEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Wendys Co — how do they compare? BridgeBio Pharma Inc trades at $82.83 (market cap $16.46B), while Wendys Co trades at $7.5 (market cap $1.41B). The key difference: BridgeBio Pharma Inc is far larger — about 11.7× Wendys Co's market cap, and Wendys Co pays a 7.55% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | WEN | |
|---|---|---|
Market Cap | $16.46B | $1.41B |
Sector | Health | Consumer Cyclical |
52-Week High | $90.17 | $11.33 |
52-Week Low | $44.81 | $6.17 |
Enterprise Value | $18.02B | $5.23B |
Dividend Yield | — | 7.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $83.08, down 3.27% today, near its 52-week high. The stock shows bullish technical momentum with strong moving averages, while fundamentals reveal rapid revenue growth to $502M in 2025 but persistent losses with a -144.4% net margin. Recent news highlights regulatory approvals for acoramidis and a $1B preferred equity raise to fund launches, driving positive sentiment despite earnings misses.
Outlook remains speculative with high execution risk; analyst consensus is strongly bullish (92% buy) targeting $104.57, but profitability challenges and heavy cash burn require successful pipeline commercialization to justify valuation. Key near-term catalysts include FDA decisions on BBP-418 and encaleret in 2026.
Wendy's (WEN) trades at $7.50, down 0.66% on the day, with a bullish technical signal and recent meme-driven momentum. The stock shows strong valuation metrics with a P/E of 9.74 and P/S of 0.65, but faces declining net income margins, falling to 7.58% in 2025. Recent earnings beats and a 7.1% dividend yield attract income investors, while Project Fresh initiatives aim to counter traffic and cost pressures.
Outlook remains mixed: low valuation and retail enthusiasm offer upside, but margin compression and high debt pose risks. Analyst consensus is cautious with a $7.96 price target, suggesting limited near-term growth. Key catalysts include Q2 2026 results on August 7 and international expansion progress, though competitive and inflationary headwinds persist.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Wendys Co
The Wendy's Company is the second-largest burger quick-service restaurant, or QSR, chain in the United States by systemwide sales, with $11.1 billion in 2021, narrowly edging Burger King ($10.3 billion) and clocking in well behind wide-moat McDonald's ($45.7 billion). After divestitures of Tim Hortons (2006) and Arby's (2011), the firm manages just the burger banner, generating sales across a footprint that spans almost 7,000 total units in 30 countries. Wendy's generates revenue from the sale of hamburgers, chicken sandwiches, salads, and fries throughout its company-owned footprint, through franchise royalty and marketing fund payments remitted by its franchisees, which account for 94% of stores, and through franchise flipping and advisory fees.
Read more on WEN →
